Skip to content
City PM
  • Germany
  • France
  • Europe
  • Markets
  • Business
  • Opinion
  • Germany
  • France
  • Europe
  • Markets
  • Business
  • Opinion
Sponsored Ad Feature is produced by an advertiser with the specific intent to promote a product and is not produced by the City PM team.
Friday 01 November 2024 9:29 am  |  Updated:  Tuesday 05 November 2024 9:23 am

Ananda Developments PLC

By:

Add as a preferred source on Google

Ananda is dedicated to developing medicines to treat complex, chronic inflammatory pain conditions. With 28 million people in the UK alone dealing with chronic pain and the NHS spending over £5 billion annually on musculoskeletal pain, there is a pressing need for better, more effective treatments.  In many conditions which exhibit complex, chronic inflammation and pain there is significant unmet need. 

Our patent-pending MRX1 medicine is being used in Phase II randomised controlled trials into:

  • chemotherapy induced nerve pain; and
  • endometriosis

As announced in October,  our patent-pending MRX2 and MRX2T assets are being used in two Phase IIIa randomised controlled trials into:

  • refractory (drug-resistant) early onset epilepsies; and
  • refractory genetic generalised epilepsies

Meet the team

Jeremy Sturgess-Smith – Finance Director – Jeremy Sturgess-Smith is a finance leader with a proven track record in corporate finance, investor relations, and strategic growth. As the first employee and a co-founder of Ananda Developments plc, Jeremy played a pivotal role in the company’s inception and spearheaded its successful IPO in July 2018. He also led the acquisitions of MRX Medical Limited, a company running two phase III studies in partnership with University College London and two phase II clinical trials in partnership with the University of Edinburgh. Beyond managing the Ananda Group’s corporate finance, audit processes, and investor relations, he oversees IT and HR as well. 

Jeremy was also a core team member of the successful IPO of URA Holdings plc in 2022 and its acquisition of the historic Gravelotte emerald mine in 2023 and Curlew Emerald Project in 2024.

LinkedIn

Ananda Developments PLC will be presenting at the 2024 Aquis Showcase

Ananda Developments PLC is proud to be a part of the 2024 Aquis Showcase, a premier event that introduces high-potential growth companies to retail investors. This event provides a valuable platform for innovative businesses like Ananda to connect with investors looking for the next generation of market leaders.

At the 2024 Aquis Showcase, Ananda Developments PLC are excited to connect with retail investors, Providing insights into its innovative solutions and the significant impact they create for businesses. The company looks forward to presenting its future growth plans and demonstrating its unwavering commitment to service excellence and sustainable success.

Learn more: https://www.aquis.eu/companies/ANA

Read more

Award winning Medtech firm excels again

Unable to generate alt text without specific article content or context. Please provide more details or context.

Share this article

  • Facebook
  • X
  • LinkedIn
  • WhatsApp
  • Email

Similarly tagged content:

Sections

  • Markets & Economics

Categories

  • Sponsored

Related Topics

  • Capital Markets
  • London business
  • Markets
  • Private markets
  • stock exchange

Trending Articles

  • Revealed: Secret Treasury plan to tax State Pension before it is paid out

  • Two solicitors linked to Post Office scandal charged with misconduct

  • Burnham’s new chief of staff ran City firm advising Thames Water and rival Heathrow bidder

  • Barclays and Lloyds join banking sector plan for digital ID

  • Clarkson’s Farm and why businesses must stop blaming the weather

More from City PM

  • Award winning Medtech firm excels again

    Partner
    Unable to generate alt text without specific article content or context. Please provide more details or context.
  • No ‘capacity’ for Ed Miliband’s warm homes plan, says British bank boss

    Property
    Breaking news coverage in a general news article, highlighting current events and important developments
  • Alkermes Announces Orphan Drug Designations for Alixorexton in the U.S. and Europe

    Business Wire
  • Brexit 10 years on: Business does not want a referendum rerun, says CBI chief

    Business
    CBI Chief Economist Newton-Smith addressing economic trends at a business conference podium with charts in the background
  • CBI: 200,000 more Brits to face unemployment this year as growth crumbles

    Economics
    People waiting outside a job centre, highlighting unemployment issues and job search challenges in the current economy.
  • Burnham refuses to rule out ‘exit tax’ as founders warn of wealth exodus

    Politics
    Andy Burnham with Labour MPs discussing party strategy at a conference setting
  • Reform UK vows to raise VAT threshold to £150,000

    Politics
    Nigel Farage, leader of Reform UK
  • Starmer dodges questions on funding for defence spending

    Politics
    Keir Starmer

City PM — European politics, business and analysis.

Europe

  • Germany
  • France
  • Europe
  • UK & Ireland

Topics

  • Business
  • Markets
  • AI
  • Technology
  • Opinion
  • Energy

More

  • Politics
  • Economics
  • Fintech
  • Legal
  • Sport
  • Life

Company

  • About City PM
  • Editorial Policy
  • Corrections
  • Contact
  • Terms of Use
  • Privacy Policy
  • Cookie Policy
© 2026 City PM · Published by CityPM Media, Bahnhofstrasse 65, 8001 Zürich, Switzerland
About · Editorial Policy · Corrections · Contact · Privacy